trending Market Intelligence /marketintelligence/en/news-insights/trending/KSS1FrQ0C1r2J_H1oKBAFw2 content esgSubNav
In This List

ViiV Healthcare commences phase 3 study of HIV infection prevention drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


ViiV Healthcare commences phase 3 study of HIV infection prevention drug

ViiV Healthcare, majority-owned by GlaxoSmithKline PLC with Pfizer Inc. and Shionogi & Co. Ltd. as shareholders, started a phase 3 study of cabotegravir, its injectable treatment for the prevention of HIV.

The study will compare the injection given every two months against the daily oral pre-exposure prophylaxis with Gilead Sciences Inc.'s Truvada. It is being conducted through a public-private collaboration of ViiV Healthcare, the HIV Prevention Trials Network, the U.S. National Institute of Allergy and Infectious Disease and Gilead Sciences.

The first phase 3 study will enroll about 4,500 men and transgender women at more than 40 sites in North and South America, Asia and Africa. A second phase 3 study for the prevention of HIV infection in young women is expected to start in 2017.